Acadia Pharmaceuticals (ACAD)

Company Description

ACADIA Pharmaceuticals (ACAD) focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. Its lead drug candidate is NUPLAZID, which has delivered positive data in Phase III pivotal trials with a pristine safety profile for the treatment of Parkinson’s disease psychosis, an unmet medical need.   The potential blockbuster is also in Phase II development for Alzheimer’s disease psychosis and is currently planning a Phase II trial for the treatment of schizophrenia. ACAD also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc.

 

COMPANY ADDRESS
3611 Valley Centre Drive; Suite 300
San Diego, CA 92130
United States

COMPANY PHONE
(858) 558-2871

COMPANY WEBSITE


Get BioInvest's perspective on Acadia's CEO

Latest Company News

A Chartists Perspective on ACADIA Pharmaceuticals Inc (ACAD) Benton Bulletin - 4 hours ago ACADIA Pharmaceuticals Inc (ACAD) presently has a 14-day Commodity Channel Index (CCI) of 58.75. The CCI was created to typically stay within the reading of -100 to +100. ACADIA Pharmaceuticals Inc. (ACAD) Lifted to Sell at BidaskClub - BNB Daily (blog) These stock's might change the kismet of Investors: TripAdvisor, Inc. (TRIP ... - StockNewsJournal [...]
Tue, Jun 27, 2017 5:48:00 PM, Continue reading at the source
Investors Are Circling ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD), What Do ... Stock Talker - 12 hours ago The Shareholder Yield of ACADIA Pharmaceuticals Inc. (NasdaqGS:ACAD) is -7.79%. The Shareholder Yield is a way that investors can see how much money shareholders are receiving from a company through a combination of dividends, share ... [...]
Tue, Jun 27, 2017 9:45:00 AM, Continue reading at the source
ACADIA: Is It The Right Time To Buy? Seeking Alpha - Jun 26, 2017 The biotech sector is back with a bang. Reports that Washington might go soft on the whole drug pricing issue has propelled the iShares Biotech ETF (NASDAQ:IBB) to above $300 for the first time in 18 months. [...]
Mon, Jun 26, 2017 5:37:00 PM, Continue reading at the source
Option Market Alert: ACADIA Pharmaceuticals Inc Implied Price Swing Hits An ... CML News - Jun 25, 2017 No Risk Alert Here: Before we dive into any analysis we simply note that ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) risk is neither elevated nor depressed. [...]
Sun, Jun 25, 2017 7:18:00 PM, Continue reading at the source
These stock's have rarely let down their investors: ACADIA Pharmaceuticals Inc ... StockNewsJournal - Jun 23, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) market capitalization at present is $3.39B at the rate of $28.68 a share. The firm's price-to-sales ratio was noted 109.54 in contrast with an overall industry average of 110.63. [...]
Fri, Jun 23, 2017 3:33:00 PM, Continue reading at the source
ACADIA Pharmaceuticals Inc. (ACAD): What's the Story? StockNewsJournal - Jun 22, 2017 ACADIA Pharmaceuticals Inc. (ACAD) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $29.27, up from yesterday's close by 3.72%. ACADIA Pharmaceuticals Inc. (ACAD) Moves Higher on Volume Spike for June 21 - Equities.com ACADIA Pharmaceuticals (ACAD) Earns Daily News Sentiment Rating of 0.27 - The Cerbat Gem [...]
Thu, Jun 22, 2017 6:33:00 PM, Continue reading at the source
Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo ... Benzinga - Jun 22, 2017 Shares of Bristol-Myers Squibb Co (NYSE: BMY) spiked to a high of $56.58 as traders circulated unconfirmed market chatter of a potential offer from Pfizer Inc. (NYSE: PFE). "Sources" say Pfizer could bid as high as $75 in cash and stock for the maker ... [...]
Thu, Jun 22, 2017 11:08:00 AM, Continue reading at the source
Why Investors remained confident on Prospect Capital Corporation (PSEC ... StockNewsJournal - Jun 21, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), maintained return on investment for the last twelve months at -68.53, higher than what Reuters data shows regarding industry's average. [...]
Wed, Jun 21, 2017 10:30:00 AM, Continue reading at the source
Taking a Look at the Data Behind ACADIA Pharmaceuticals Inc. (ACAD) StockNewsJournal - Jun 8, 2017 ACADIA Pharmaceuticals Inc. (ACAD) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $25.45, down from yesterday's close by -2.71%. Why ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) Stock Is A Buy Near $25 - BNL Finance (press release) (registration) (blog) ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) added to 39 new portfolios - Post Analyst [...]
Thu, Jun 08, 2017 5:03:00 PM, Continue reading at the source
ACADIA Pharmaceuticals Draws Value From Nuplazid Revenue Stream Seeking Alpha - May 31, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is going through a phase common to most first-timers in the post-approval scenario: it is seeing some anticlimactic movement after the high expectations prior to the PDUFA. Zacks: Analysts Anticipate ACADIA Pharmaceuticals Inc. (ACAD) Will Announce ... - BNB Daily (blog) Analysts Showing Optimistic Trends For ACADIA Pharmaceuticals Inc. (ACAD) - News Oracle [...]
Wed, May 31, 2017 1:18:00 PM, Continue reading at the source